within Pharmacolibrary.Drugs.ATC.C;

model C03XA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.56,
    Cl             = 4.24 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007166666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Tolvaptan is a selective vasopressin V2-receptor antagonist used for the treatment of hyponatremia (low sodium levels in the blood) due to syndrome of inappropriate antidiuretic hormone secretion (SIADH), heart failure, and autosomal dominant polycystic kidney disease (ADPKD). It is an approved oral medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Shoaf, SE, et al., &amp; Mallikaarjun, S (2014). Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. <i>Kidney international</i> 85(4) 953–961. DOI:<a href=&quot;https://doi.org/10.1038/ki.2013.350&quot;>10.1038/ki.2013.350</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24048380/&quot;>https://pubmed.ncbi.nlm.nih.gov/24048380</a></p></li><li><p>Kim, SR, et al., &amp; Azuma, J (2011). Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. <i>Cardiovascular drugs and therapy</i> 25 Suppl 1 S5–S17. DOI:<a href=&quot;https://doi.org/10.1007/s10557-011-6299-3&quot;>10.1007/s10557-011-6299-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22120090/&quot;>https://pubmed.ncbi.nlm.nih.gov/22120090</a></p></li><li><p>Yi, S, et al., &amp; Yu, KS (2012). Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men. <i>Journal of cardiovascular pharmacology</i> 59(4) 315–322. DOI:<a href=&quot;https://doi.org/10.1097/FJC.0b013e318241e89c&quot;>10.1097/FJC.0b013e318241e89c</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22130104/&quot;>https://pubmed.ncbi.nlm.nih.gov/22130104</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C03XA01;
